Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial ...
Arch Biopartners announces Alberta Health Services approval for Phase II trial of LSALT peptide to prevent and treat cardiac surgery-associated acute kidney injury (CS-AKI). The trial, an international, multi-center, randomized, double-blind, placebo-controlled study, aims to evaluate the percentage of subjects with AKI within seven days following on-pump cardiac surgery, as defined by KDIGO criteria.
Highlighted Terms
Related News
Arch Biopartners Inc. announces Alberta Health Services approval for Phase II trial of LSALT peptide for preventing cardiac surgery-associated acute kidney injury (CS-AKI). The trial, targeting 240 patients, aims to evaluate AKI incidence within seven days post-surgery using KDIGO criteria. Recruitment begins in September at University of Calgary, Toronto General Hospital, and St. Michael's Hospital, with additional sites in Turkey.
Arch Biopartners announces Alberta Health Services approval for Phase II trial of LSALT peptide to prevent and treat cardiac surgery-associated acute kidney injury (CS-AKI). The trial, targeting 240 patients, is set to begin recruitment in September at multiple international sites.
Arch Biopartners announces Alberta Health Services approval for Phase II trial of LSALT peptide to prevent and treat cardiac surgery-associated acute kidney injury (CS-AKI). The trial, an international, multi-center, randomized, double-blind, placebo-controlled study, aims to evaluate the percentage of subjects with AKI within seven days following on-pump cardiac surgery, as defined by KDIGO criteria.
Arch Biopartners Inc. announced Alberta Health Services approved the Phase II trial for LSALT peptide to prevent and treat cardiac surgery-associated acute kidney injury (CS-AKI). The trial, recruiting 240 patients, aims to evaluate AKI incidence within seven days post-surgery using KDIGO criteria. LSALT peptide targets dipeptidase-1 (DPEP1) to prevent ischemia-reperfusion injury, with findings published in Science Advances.